Micro-RNAs-122 and Pro-neurotensin biomarker for non-invasive diagnosis of Non-alcoholic fatty liver disease (A Case control study).

BACKGROUND

With a prevalence of 24% worldwide, nonalcoholic fatty liver disease (NAFLD) is regarded as a major risk factor for liver-related morbidity and death. The current gold standard for diagnosing the severity of non-alcoholic fatty liver is liver biopsy. Instead of using invasive procedures to identify nonalcoholic fatty liver, it is imperative to create non-invasive diagnostic methods. Goal: The purpose of our case-control study was to investigate the potential non-invasive biomarker significance of serum pro-neurotensin and circulating miRNA-122 for the diagnosis of non-alcoholic fatty acid disorders.

METHODS

For fifty individuals with confirmed NAFLD, clinical evaluations, lab tests, and anthropometric measures were recorded. A control group of fifty people who appeared to be in good health was enlisted. Pro-neurotensin and micro-RNAs 122 were measured in serum samples.

RESULTS

Serum proneurotensin levels had 83.4% sensitivity and 82.7% specificity at a cut-off ≥ 106, whereas mi-RNA-122 showed a rise in levels in NAFLD (p <0.05). At a cut-off ≥ 6.71, mi-RNA-122 exhibited 53% sensitivity and 72% specificity to distinguish NAFLD from healthy controls.

CONCLUSION

To diagnose NAFLD cases, the combination of serum pro-neurotensin and circulating mi-RNA-122 may be helpful. To learn more about the potential contribution of pro-NT and mi-RNA-122 to the onset, course, and prognosis of NASH, large-scale research is required.